Reading the Claim 1 verbatim of Imperial Chemical Industries Ltd's Zoladex®-line PLA-PLGA peptide sustained-release patent US4767628 (filed 1987-07, granted 1988-08) in pharmaceutical delivery context — the 'prostate cancer therapy Zoladex core patent' that sat silent for 36 years behind the candidates.tsv label 'CS-008 Ajinomoto kojic acid' (excavation memo)

About this memo: This memo is the reality reading of CS-008 US4767628, confirmed as a swap in ep76 (cosmetic-patent-04). Same structure as ep77 (which addressed CS-007 US5851538's APS Microsponge retinol patent), this memo reads Imperial Chemical Industries Ltd's (ICI, now AstraZeneca) Zoladex®-line PLA-PLGA peptide sustained-release patent at Claim 1 verbatim level and translates it into pharmaceutical delivery context. No direct cosmetic relevance, but the distant relation to medical aesthetics' Sculptra PLLA filler is organized at the end.

Patent identity

ICI Pharmaceuticals was spun off as Zeneca in 1993, and merged with Sweden's Astra in 1999 to form the current AstraZeneca. At the time of this filing (1987), Francis G. Hutchinson was the sole inventor as an ICI Pharmaceuticals researcher, establishing the delivery form for Zoladex® goserelin. Zoladex itself was approved in the UK in 1989 and the US in 1990, and currently maintains global annual sales of $300-500 million, remaining one of AstraZeneca's flagship pharmaceuticals.

Claim 1 verbatim

1. A pharmaceutical composition comprising (a) from 50% to 99.999% of a polylactide which is a polymer of lactic acid alone, a copolymer of lactic acid and glycolic acid wherein the ratio of glycolide to lactide units is from 0 up to 3:1, a mixture of such polymers, a mixture of such copolymers, or a mixture of such polymers and copolymers, the lactic acid being either in racemic or in optically active form, and such polylactide being either soluble in benzene and having an inherent viscosity of from 0.093 (1 g. per 100 ml. in chloroform) to 0.5 (1 g. per 100 ml. in benzene), or insoluble in benzene and having an inherent viscosity of from 0.093 (1 g. per 100 ml in chloroform) to 4 (1 g. per 100 ml in chloroform or dioxan), and (b) from 0.001% to 50% of a pharmacologically active polypeptide which has a molecular weight at least about the same as the molecular weight of tetragastrin, which is not significantly hydrolized under the conditions encountered within the composition during the period of use envisioned, and which contains four or more amino acid residues, said polypeptide being uniformly dispersed in said polylactide, which composition, when placed in an aqueous physiological-type environment absorbs water and exhibits two successive phases of release of polypeptide, the first phase being release by initial diffusion through aqueous polypeptide domains communicating with the exterior surface of the composition, and the second phase being [matrix degradation release].

Decompose into six elements.

1. Polylactide-system matrix: (a) homopolymer of lactic acid, or copolymer of lactic acid and glycolic acid (glycolide:lactide ratio 0 to 3:1), or mixtures. Lactic acid in racemic or optically active form (D, L, DL all permitted).
2. Polylactide content: 50% to 99.999% w/w. Main component of the composition.
3. Polylactide viscosity range: (i) benzene-soluble with inherent viscosity 0.093 (chloroform 1g/100ml) to 0.5 (benzene 1g/100ml), or (ii) benzene-insoluble with inherent viscosity 0.093 (chloroform) to 4 (chloroform or dioxan). Typical Claim phrasing for specifying PLA / PLGA molecular weight (hundreds to hundreds of thousands of Da) via viscosity.
4. Pharmacologically active polypeptide content: 0.001% to 50% w/w.
5. Polypeptide specifications: (i) molecular weight ≥ tetragastrin (tetragastrin is the 4-residue gastrin fragment, MW ~597 Da), (ii) not significantly hydrolyzed under conditions of use, (iii) contains four or more amino acid residues. → Limits to 'reasonably stable peptide drugs, excluding short pH-unstable peptides.' Goserelin (10-residue peptide, MW ~1269 Da) qualifies.
6. Two-phase sustained-release behavior: (i) first phase = initial diffusion through aqueous polypeptide domains communicating with exterior surface, (ii) second phase = matrix degradation. Achieves 1-3 month sustained release.

The narrowest of the six are (5) polypeptide MW / residue specifications and (6) two-phase sustained release behavior. The former excludes short-chain peptides and non-peptide small molecules; the latter excludes single-phase release (diffusion-only or degradation-only).

Claims 2-17 overview

Claims 2-7 specify polylactide molecular weight / viscosity sub-ranges. Claims 8-12 specify polypeptide species (goserelin, buserelin, leuprolide, triptorelin, etc., LH-RH agonists; and somatostatin analogs like octreotide). Claims 13-15 specify sustained-release periods (1-30 days, 30-90 days, >90 days). Claims 16-17 cover physical form (implant, microspheres, rods) and sterilization conditions.

The broadest claim in pharmaceutical delivery technology is Claim 1 itself, by which this patent enclosed the entire class of PLA / PLGA × polypeptide sustained-release agents for the 20 years 1988-2008.

Lineage of Zoladex® goserelin

Zoladex® is an LH-RH (luteinizing hormone-releasing hormone) agonist developed by ICI Pharmaceuticals in the 1980s; the active ingredient goserelin acetate is a 10-residue synthetic peptide (pyroGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-AzaGly-NH2). By continuously stimulating the LH-RH receptor, it desensitizes pituitary sensitivity, lowering blood testosterone (men) or estrogen (women) to chemical castration levels. Clinical applications: (a) advanced prostate cancer (testosterone-dependent, lowering to castration levels), (b) breast cancer (premenopausal hormone-dependent breast cancer), (c) endometriosis (estrogen-dependent lesions), (d) IVF (controlled ovarian hyperstimulation).

Through the PLA / PLGA × polypeptide sustained-release form enclosed by US4767628, Zoladex is formulated as 1-month sustained (3.6 mg implant) and 3-month sustained (10.8 mg implant) subcutaneous injection implants. Patients are switched from daily oral administration to monthly / quarterly clinic injections, dramatically improving prostate cancer therapy adherence. Zoladex has maintained global annual sales of $300-500 million as one of AstraZeneca's flagship oncology products since 1989 UK / 1990 US approval.

Successor PLA-PLGA sustained-release product groups

Starting from (or in parallel with) US4767628's Claim 1, the following major PLA-PLGA sustained-release pharmaceuticals were launched.

1. Lupron Depot (leuprolide acetate, Takeda / Abbott, US approval 1989) — Same LH-RH agonist sustained-release injection, 1-month / 3-month / 4-month / 6-month formulations. Prostate cancer, endometriosis, precocious puberty.
2. Trelstar (triptorelin pamoate, Watson Pharmaceuticals → Allergan → Verity Pharmaceuticals, US approval 2000) — Same LH-RH agonist, 1-month / 3-month / 6-month formulations.
3. Sandostatin LAR Depot (octreotide acetate, Novartis, US approval 1998) — Somatostatin analog sustained-release injection, monthly formulation. Acromegaly, carcinoid syndrome, VIPoma.
4. Vivitrol (naltrexone for extended-release injectable suspension, Alkermes, US approval 2006) — Monthly formulation for opioid and alcohol dependence treatment. Naltrexone is a small molecule, not a peptide, but adopts PLG microsphere sustained release.
5. Bydureon (exenatide extended-release, Amylin / AstraZeneca, US approval 2012) — Weekly GLP-1 receptor agonist for type 2 diabetes treatment.

Coverage by Claim 1 splits depending on whether they meet the '4+ residue peptide × PLA / PLGA × two-phase sustained release' requirement (Vivitrol's naltrexone is small-molecule and doesn't qualify; Bydureon's exenatide is a 39-residue peptide and qualifies).

Distant relation to cosmetics — Sculptra PLLA filler

CS-008 US4767628 has no direct cosmetic relevance. However, the medical aesthetics field has Sculptra (PLLA filler, poly-L-lactic acid filler), approved by the US FDA in 2009 / Japan in 2014 / Europe (as NewFill) in 1999 as a 'collagen biostimulator that gradually degrades after intradermal injection while inducing collagen synthesis.' Product flow: Sanofi-Aventis → Galderma.

Zoladex (PLA degradation × peptide release) and Sculptra (PLLA degradation × collagen induction) differ only in how the same in vivo PLA degradation reaction is applied — the former aims to release drug upon degradation, while the latter aims for the degradation itself (and as a foreign-body response side product).

So beyond cosmetic subseries Phase 2 'delivery patents,' CS-008 US4767628 and its successor Sculptra-related patent group are also important themes as candidates for spinning off into Phase 3 'medical aesthetics subseries.' Day 22+ meta-review will discuss boundary design between cosmetic subseries Phase 2 / Phase 3.

Day 22+ excavation candidates

Three excavation candidates derived from this memo are proposed.

1. Zoladex® goserelin active peptide structure patent: US4767628 is a delivery patent. The structure patent for the active peptide goserelin itself is presumed to be US4100274 (1978, ICI, Roger W. Roeske et al., or different inventors). Retrieve and translate Claim 1 verbatim into pharmaceutical context.
2. Sculptra PLLA filler-related patent group: Sanofi-Aventis (NewFill, 1999 European approval) → Sculptra Aesthetic (US FDA 2009) regulatory approval-related US / European patents Claim 1 verbatim retrieval. Candidate numbers for medical aesthetics subseries Phase 3.
3. Lupron Depot and Trelstar delivery patents: Takeda / Abbott's Lupron Depot (leuprolide × PLG microsphere sustained release) core patent US4849228 etc. retrieval. Confirm boundary lines of PLA-PLGA sustained-release class as Zoladex-line extension.

These are proposed for registration as new categories in candidates.tsv in Day 22+: 'Pharmaceutical Delivery Patents' and 'Medical Aesthetics Subseries' (Google Sheets direct input not available; handed off to Haruko).

Day 21 session summary across ep76 / ep77 / ep78

Day 21 session = ep76 (DB correction tale + structural explanation) + ep77 (CS-007 APS Microsponge retinol reality reading) + ep78 (CS-008 ICI Zoladex-line PLA-PLGA peptide sustained-release reality reading), three episodes = note 1 + memo 2 structure, updating cosmetic subseries Phase 1 candidates.tsv DB corrections to 11 cases / 47 label discrepancies. Next session (Day 22) addresses excavation of the correct P&G niacinamide whitening patent (candidate US5939082) and correct kojic acid whitening patent (candidate JP S58-118507 / Sansho Pharmaceutical), and independence consideration for Phase 2 'cosmetic delivery patents' and Phase 3 'medical aesthetics subseries.'